AIMS AND BACKGROUND: Neuroblastoma is the most common solid extracranial tumor in children. The median age of onset is 2 years, with more than 95% of patients younger than 10 years at diagnosis. As neuroblastoma is rare in adolescents and exceedingly rare in adults, few series are reported in the literature. In the present study, we analyzed the outcomes and clinical characteristics of a mono-institutional series. METHODS: We describe 27 consecutive patients over 12 years of age (range, 12-69) with previously untreated neuroblastoma treated at our Institution between 1982 and 2001. RESULTS: Overall survival at 5 and 10 years was 40% and 20%, respectively, and progression-free survival at 5 and 10 years was 18%. In the present series, there was a long interval between the onset of signs/symptoms and diagnosis, and between recurrence/progression and death. None had MYCN amplification. CONCLUSIONS: The passive course of the disease in most of our patients did not reflect a more favorable outcome compared with younger patients, thus suggesting a possible genetically different subset of neuroblastoma in older patients.
AIMS AND BACKGROUND: Neuroblastoma is the most common solid extracranial tumor in children. The median age of onset is 2 years, with more than 95% of patients younger than 10 years at diagnosis. As neuroblastoma is rare in adolescents and exceedingly rare in adults, few series are reported in the literature. In the present study, we analyzed the outcomes and clinical characteristics of a mono-institutional series. METHODS: We describe 27 consecutive patients over 12 years of age (range, 12-69) with previously untreated neuroblastoma treated at our Institution between 1982 and 2001. RESULTS: Overall survival at 5 and 10 years was 40% and 20%, respectively, and progression-free survival at 5 and 10 years was 18%. In the present series, there was a long interval between the onset of signs/symptoms and diagnosis, and between recurrence/progression and death. None had MYCN amplification. CONCLUSIONS: The passive course of the disease in most of our patients did not reflect a more favorable outcome compared with younger patients, thus suggesting a possible genetically different subset of neuroblastoma in older patients.
Authors: Maya Suzuki; Brian H Kushner; Kim Kramer; Ellen M Basu; Stephen S Roberts; William J Hammond; Michael P LaQuaglia; Suzanne L Wolden; Nai-Kong V Cheung; Shakeel Modak Journal: Int J Cancer Date: 2018-04-06 Impact factor: 7.396
Authors: Jun S Wei; Peter Johansson; Li Chen; Young K Song; Catherine Tolman; Samuel Li; Laura Hurd; Rajesh Patidar; Xinyu Wen; Thomas C Badgett; Adam T C Cheuk; Jean-Claude Marshall; Patricia S Steeg; José P Vaqué Díez; Yanlin Yu; J Silvio Gutkind; Javed Khan Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240
Authors: Ana P Berbegall; Eva Villamón; Irene Tadeo; Tommy Martinsson; Adela Cañete; Victoria Castel; Samuel Navarro; Rosa Noguera Journal: Neoplasia Date: 2014-06 Impact factor: 5.715
Authors: Elisa Rogowitz; Hani M Babiker; Mohammed Kanaan; Rebecca A Millius; Q Scott Ringenberg; Maria Bishop Journal: Exp Hematol Oncol Date: 2014-07-17